title: Less menorrhagia for women with VTE.
abstract: In this issue of Blood, Martinelli et al provide reassuring data that women taking oral anticoagulant therapy for venous thromboembolism (VTE) may use estrogen or progestin hormonal therapy to control the menstrual bleeding without increased risk for recurrent thromboembolism.
authors.affiliation: McMASTER UNIVERSITY.
authors.forename: Sam
authors.identifier: http://orcid.org/0000-0002-8512-9043
authors.initials: S
authors.lastname: Schulman
mesh_terms: D000925:Anticoagulants / Q000009:adverse effects*; D017984:Enoxaparin / Q000009:adverse effects*; D004967:Estrogens / Q000009:adverse effects*; D005260:Female; D006801:Humans; D011372:Progestins / Q000009:adverse effects*; D000069552:Rivaroxaban / Q000009:adverse effects*; D014592:Uterine Hemorrhage / Q000139:chemically induced*; D054556:Venous Thromboembolism / Q000139:chemically induced*
chemical_list: D000925:Anticoagulants; D017984:Enoxaparin; D004967:Estrogens; D011372:Progestins; D000069552:Rivaroxaban